Did Ardelyx beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Ardelyx year over year?

What were the key takeaways from Ardelyx’s earnings call?

What factors drove the changes in Ardelyx's revenue and profit?

What is Ardelyx's latest dividend and current dividend yield?

What were the key takeaways from Ardelyx's earnings call?

What is Ardelyx's gross profit margin?

What is the market's earnings forecast for Ardelyx next quarter?

- **IBSRELA Breakthrough**: 92% YoY growth to $78.2 million, driven by patient satisfaction (85%+ adherence) and expanded prescriber engagement. ARDX-10531's preclinical success signals a return to pipeline development, with potential in broader NHE3-related indications. - **XPHOZAH Resilience**: 9% QoQ growth amid market turbulence, Ardelyx's ability to maintain stability underscores operational excellence. - **Strategic Reinvestment**: ARDX-10531 leverages existing expertise to diversify revenue streams, aligning with the company's $1 billion peak sales target for IBSRELA. - **Financial Discipline**: Stable gross to net metrics (~31% IBSRELA, ~29% XPHOZAH) reflect Ardelyx's ability to navigate challenges while investing in growth, the company's balance sheet remains strong, supporting future initiatives.

**【Management Opening Remarks】**
- Ardelyx delivered strong Q3 2025 performance with record-high revenue of $110.3 million, driven by 92% YoY growth in IBSRELA and 9% QoQ growth in XPHOZAH. The company announced ARDX-10531, a next-gen NHE3 inhibitor, signaling a return to pipeline development. CEO Michael Raab emphasized the team's ability to balance commercial execution with strategic investments.

**【CEO Commentary】**
- IBSRELA achieved $78.2 million in Q3 revenue, surpassing prior records. The molecule's differentiated mechanism addresses unmet needs in IBS-C, with 75% of patients reporting satisfaction. ARDX-10531 represents a potential expansion into broader therapeutic areas, leveraging Ardelyx's expertise in NHE3 inhibition, the company aims to generate $1 billion in peak sales, the leadership team highlighted disciplined capital allocation and pipeline development.

**【CFO Commentary】**
- Q3 gross to net deductions remained stable at ~31% for IBSRELA and ~29% for XPHOZAH, reflecting strong demand despite market turbulence. The company raised 2025 guidance to $270-275 million in IBSRELA revenue, driven by expanded prescriber engagement and pull-through improvements. The balance sheet remains robust with $242.7 million in cash, supporting future pipeline investments.

**【Q&A Highlights】**
- ARDX-10531's preclinical data demonstrates high potency and solubility, opening opportunities in hypertension, heart failure, and diabetes. The company plans to advance the molecule through Phase 1, aligning with strategic priorities to balance commercial execution with pipeline growth. The team is confident in maintaining momentum despite market challenges, with IBSRELA and XPHOZAH contributing to long-term value creation.

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ARDX

ARDX fundamentals

You can ask Aime